The serum of some patients with insulin-resistant "diabetes" contains antibodies that bind to and block the cell membrane receptors for insulin. In this report, we have characterized the effects of the antireceptor antibodies on the interaction of 125 I-insulin with its receptor on the human lymphoblastoid cell line IM-9. Up to 95% of specific insulin binding can be inhibited by pretreatment of the cells with these immunoglobulins. The onset of the inhibitory effect is time-and temperature-dependent, and the effect is reversed extremely slowly if the cells are suspended in a large excess of antibody-free buffer. These features of antibody binding can be easily distinguished from those for insulin binding to its receptor. The inhibitory effect of the antibodies can be reversed by exposure of the cells to conditions known to elute surface immunoglobulins.
INTRODUCTION
We have recently described two clinical syndromes characterized by severe insulin resistance, acanthosis nigricans, and a marked defect at the level of the membrane receptor for insulin (1) . These two syndromes, referred to as types A and B, can be distinguished on clinical grounds, and by the fact that type B patients have a circulating inhibitor of insulin receptor binding (2) . In a previous report, we have shown that the circulating inhibitors in these patients are polyclonal immunoglobulins, primarily of the IgG class, and that their inhibitory activity is mediated through the F(ab')2 portion of the molecule (3). Further, several lines of evidence strongly suggest that these antibodies act by binding directly to determinants on, or intimately linked to, the insulin receptor molecule (2) (3) (4) . Thus, these immunoglobulins may be considered to be "antireceptor antibodies" such as those which have been proposed as etiologic factors in Graves' disease (5) and myasthenia gravis (6) .
Our initial description and characterization of these antibodies was based on a simple assay in which normal cells or membranes were exposed to serum or immunoglobulin fractions for 1 h at 40 or 22°C, thoroughly washed, and then exposed to 1251-insulin for binding assay (2, 3) . In this report, we explore in more detail the effects of these antireceptor antibodies on 1251-insulin binding to its receptors on the human lymphoblastoid cell of the IM-9 line. We report data on (a) the kinetics of onset and reversal of antibody action, (b) the variable effects of these antibodies on the kinetics of insulin association, dissociation, and insulin-induced negative cooperativThe Journal of Clinical Investigation Volume 60 October 1977-784 -794 ity, and (c) the effects of these antibodies on the affinity and number of residual insulin receptors. Taken together, these data indicate that antibodies to the insulin receptor impair insulin binding by a variety of mechanisms, and that sera from different patients may differ in the precise locus of their actions.
METHODS
Human lymphoblastoid cells (I M-9), maintained in continuous culture in plastic flasks, were grown to stationary phase at 37°C in Eagle's Minimum Essential Medium (National Institutes of Health Media Unit) supplemented with 10% fetal calf serum, penicillin, and streptomycin. Glutamine (0.26 mg/ml) was adlded to the medium just before transfer of the cells on the day of feeding. Cells were split twice a week and fresh media was added. Viability of cells was monitored by trypan blue dye exclusion and was always >90%. Previous studies (7) have shown that insulin receptors on these cells have binding properties essentially identical to those of insulin receptors on more classic targets of insulin action such as liver (8) and fat (9) . Porcine insulin (Eli Lilly Co., Indianapolis, Ind.) was iodinated to a sp act of 100-200 ACilt,g by a modification of the chloramine-T method (10) .
All sera were obtained after an overnight fast and were stored at -20°C until use. The notation for identification of sera corresponds to that employed in a previous publication (1) .
Preincubation with serum. IM-9 cells were sedimented and resuspended at a concentration of 15 x 106/ml in an assay buffer containing 100 mM Hepes, 120 mM NaCl, 1.2 mM MgSO4, 2.5 mM KCl, 10 mM glucose, 1 mM EDTA, and 1% bovine serum albumin, pH 7.6. Patient or control sera were diluted with phosphate-buffered saline (PBS),' pH 7.6, and then incubated for various periods at the indicated temperatures with an equal volume of the cell suspension to give the final serum dilution as indicated in the legend to the figures. After preincubation, cells were washed three times with 3 vol of PBS and resuspended in assay buffer at a concentration of 15 x 106 cells/ml for insulin binding study. Previous studies have shown (2) that exposure of cells to normal serum to which high concentrations of insulin (50 ng/ml) have been added causes no reduction of subsequent '251-insulin binding under these conditions of preincubation and extensive washing.
Insulin binding studies. After preincubation of cells as described, the binding of '251-insulin to these cells was determined in a variety of ways: (a) the effects of duration and temperature of serum preincubation on binding inhibition; (b) the time-course and temperature dependence of recovery of binding in the absence of serum; (c) the reversal of binding inhibition by acid wash; (d) the effect of serum treatment on association rate of '25I-insulin; (e) the effect of serum treatment on dissociation rate of '25I-insulin in the presence and absence of unlabeled insulin; (f) the effect of serum treatment on steady-state insulin binding. at all levels of receptor occupancy and is referred to as the "average affinity profile" (13) . In this analysis, the limiting high affinity state, obtained at low levels of receptor occupancy, is designated K, (affinity of the empty receptor), and the limiting low affinity state, obtained at high levels of receptor occupancy, is Kf (affinity of the filled receptor).
RESULTS
Effect of preincubation with undiluted sera on subsequent insulin binding. Undiluted sera from six patients with extreme insulin resistance (types A and B) were assayed for ability to inhibit insulin binding to IM-9 lymphocytes after preincubations of increasing durations at 37°C (Fig. 1) . The two sera (B-2 and B-3) from the type B patients who displayed the greatest clinical insulin resistance produced nearly maximal inhibition after 5 min of preincubation. With these sera, 96 and 90% of specific binding were prevented, respectively. Serum B-1, obtained from a patient with less severe insulin resistance, produced a time-dependent increase in inhibition, with maximal effect not yet obtained after 3 h. Sera A-1, A-2, and A-3, obtained from patients with insulin resistance and a severe insulin receptor deficiency with an apparently distinct etiologic basis (1), caused no significant inhibition of binding after 3 h of preincubation at 37°C. It is notable that serum insulin concentrations in these type A patients were comparable to those of type B patients, thus providing an internal control against a possible role for insulin in the production of the observed inhibitory effect.
Effect of duration and temperature of preincubation on subsequent insulin binding. course of onset of inhibitory effect in these three sera, cells were preincubated with dilutions of sera designed to produce comparable reductions of binding (about 50% of control; Fig. 2 ). These dilutions were 1:4, 1:4,000, and 1:80 for sera B-1, B-2, and B-3, respectively. Under these conditions, sera B-2 and B-3 showed rates of onset of inhibition that were greater at 37°C than at 22°C, which in turn were greater than that at 4°C. With serum B-1, there was a different temperature dependence, with 220 > 370> 40C. Because maximum inhibition had not been reached at every temperature by 180 min, it is uncertain whether temperature affected only rate of onset of inhibition (and presumably antibody binding) or maximal extent of inhibition as well. It should be noted that sera A-1, A-2, and A-3, which produced no binding inhibition at 370C (Fig. 1) , also had no effect at 40 or 22°C (data not shown).
Reversal of inhibitory effects. When compared to the time-course of onset of antibody inhibition of insulin binding, cells treated with serum B-2 were slow to recover insulin binding when washed and re- tion. 30 x 106 IM-9 lymphocytes in 1.5 ml of assay buffer were incubated at 22°C for 60 min with either 1.5 ml of a 1:2,000 dilution of serum B-2 (to give a final dilution of 1:4,000) or with an equal volume of assay buffer alone.
After preincubation, cells were washed three times with 6 ml of PBS at 22°C, and then resuspended in 3 ml of assay buffer at 4°C. Duplicate 100-,ul samples of the resuspended cell suspensions were added to tubes containing 5.0 ml of assay buffer at 37°, 22°, or 4°C. After 1, 2, or 3 h, cells were sedimented, and the pellet was resuspended in 0. To further explore the reversible nature of antibody-mediated binding inhibition, we exposed normal cells and cells which had been antibody-treated to wash conditions known to elute antibodies from cell membranes (14; Fig. 4 ). Cells in which insulin binding had been reduced by preincubation with antibody showed a threefold increase of insulin binding after acid wash, suggesting that the inhibition of binding caused by the antibody can be reversed after the antibody is eluted. The level of binding did not return entirely to normal, however, probably as a result of damage to the receptor caused by the acid conditions of the wash. Brief exposure of normal cells to the same wash conditions resulted in a reduction in binding to the same level as observed in the antibody-treated cells which had been acid washed. In a previous study, with 125I-labeled (m)n FIGuRE 4 Reversal of antireceptor antibody effect by acid wash. 3 x 106 IM-9 lymphocytes in 0.2 ml of assay buffer were incubated at 22°C for 60 min with 0.2 ml of serum B-2 diluted 1:100 in assay buffer or with buffer alone. After preincubation, cells were washed three times in 1 ml of PBS pH 7.6 at 22°C. After the third wash, cell pellets were resuspended in 1.0-ml vol of either a glycine HC1 buffer, pH 3.0, that contained 3 mg/ml bovine serum albumin (14) or assay buffer, pH 7.6, for 1 or 10 min, as indicated. Cells were then sedimented, washed twice in 2 ml of assay buffer, and finally resuspended in 0.5 ml of assay buffer for insulin binding assay as described in the legend to In INSULIN (ng/ml) FIGURE 5 Effect of antireceptor antibody on insulin binding at steady state. 3 x 106 IM-9 lymphocytes in 0.2 ml of assay buffer were incubated at 22°C for 60 min with 0.2 ml of dilutions of each sera, to give the final dilutions as indicated. Cells were then washed as described in the legend to Fig. 1 , and the pellets were resuspended in tubes containing 0.5 ml of assay buffer, 100 pg of '25I-insulin, and different amounts of unlabeled insulin, as seen on the horizontal axis. After incubation at 15°C for 90 min, duplicate 200-,ul samples were removed, and the 1251-insulin bound to the pellet was determined as described in the legend to Fig. 1 . B/F of the labeled hormone is plotted as a function of the total insulin in each tube.
plots are obtained (Fig. 6) reduction in steady-state binding observed at low hormone concentration.
To help clarify this parameter, we have used the average affinity profile (13) , in which the average affinity of the system is plotted as a function of receptor occupancy (Fig. 7) . With this graphic method it is apparent that the average affinity of the insulin receptor is reduced, to variable degrees by different sera, particularly at low degrees of receptor occupancy. The limiting high affinity obtained at low occupancy, Ke, ranges from 11% of control with high concentrations of serum B-2 to 90% of control for serum B-1 (Table I) . With increasing saturation by insulin, the K of the antibody-treated cells approaches that of controls, and the two are very similar at kf, the limiting low affinity. Thus, the overall reduction in steady-state binding caused by these antibodies is the result of variable reductions of both receptor (Fig. 9) . The calculated rate constants (k) were seen to be reduced by serum treatment; with the highest serum concentration, a fivefold reduction of k was produced. Thus, reduction of association rate constant for insulin binding would appear to contribute to the reduced affinity of hormone binding to cells pretreated with serum B-2.
To assess the possibility that binding of antibody to the receptor could induce the phenomenon of negative cooperativity, and thereby account in part for the reduced affinity of antibody-treated cells for insulin, we examined the effect of purified antibody on the dissociation of preboun-d 1251-insulin (Table II) . Addition to the dilution medium of an amount of antibody (from serum B-2) sufficient to cause an 80% reduction of tracer insulin binding had no effect on the dissociation rate of 1251-insulin bound to control cells when compared to the dissociation rate observed by dilution alone. This contrasts markedly with the ability of unlabeled insulin in the dilution medium to accelerate the dissociation of bound hor-B/R. x 100 (FRACTIONAL OCCUPANCY) FIGURE 8 Effect of antireceptor antibody on association of 1251-insulin. 30 x 106 IM-9 cells in 2.0 ml of assay buffer were incubated for 1 h at 20°C with 2.0 ml of serum to produce the indicated dilution, or with buffer. After three washes with 10 cm3 of buffer at 4°C, cells were resuspended in 2.0 cm3 of assay buffer at 15°C. In each case, 500 pg of 1251I_ insulin was added both in the presence and absence of 10 ,ug/ml unlabeled insulin. At indicated time-points, duplicate 100-,ul samples were removed and sedimented through 200 ,ul of cold buffer in microfuge tubes, the supemates were aspirated, and the 125I1 insulin bound to the pellets determined. Specific B/F of the labeled hormone on the vertical axis is plotted as a function of time.
mone under identical conditions. In this experiment, the accelerated dissociation of bound insulin by unlabeled hormone is indicative of the negatively cooperative site-site interactions that are a consequence FIGuRE 9 The data for the binding of 1251-insulin to IM-9 cells with and without pretreatment with serum B-2 ( Fig. 8) was applied to the second order rate equation where b = a = H0, and x = bound hormone. The total Ro after treatment with buffer or serum in each case was determined at steady state using Scatchard analysis in a separate experiment (data not shown). The plots were linear over the first 10 min of association, and the rate constant (k) was calculated by solution of the preceding equation. of insulin binding to its receptor (12) . The effect of serum pretreatment on dissociation of insulin subsequently bound to the cell was also assessed. Cells were first treated with serum or buffer, and then allowed to bind labeled hormone, after which dissociation of tracer was measured by dilution of cells in a large excess of buffer as above. In addition, the effect of unlabeled insulin on dissociation of tracer by dilution was determined (12) . Pretreatment of cells with sera B-1, B-3, and the lower concentration of B-2 (which produced comparable degrees of insulin binding inhibition) had no significant effect on spontaneous dissociation of 1251-insulin at 15°C (Fig. 10) .
The higher concentration of serum B-2 produced a small (15-20%) but highly reproducible effect on spontaneous dissociation. On the other hand, preincubation with each serum caused unlabeled insulin to be less effective in accelerating the dissociation of bound 125I-insulin from these cells. This effect was most pronounced with serum B-3 and with the higher concentration of B-2. Treatment with serum B-2 caused a rightward shift in the dose-response curve for insulin-induced acceleration of insulin dissociation, whereas treatment with sera B-1 and B-3 caused less enhancement of dissociation at each concentration of insulin (Fig. 11) . DISCUSSION Peptide hormones and neurotransmitters initiate their actions through binding to specific receptors on the cell membrane (15) . Defects at the level of the receptor would be expected to influence hormone action, and such defects might be expected to arise from a wide variety of possible mechanisms, both intrinsic and extrinsic to the cells in question. An interesting new mechanism by which receptor dysfunction may arise is the development of autoantibodies directed against specific membrane receptors (16). Such antireceptor antibodies are currently being MINUTES OF DISSOCIATION FIGURE 10 Effect of antireceptor antibody on dissociation of 1251-insulin from IM-9 lymphocytes. IM-9 cells were pretreated with serum or buffer, washed, and then incubated with 1251-insulin at 15'C, in the presence and absence of 10 ug/ml of unlabeled insulin, as described in the legend to Fig. 8 . After 90 min of incubation, 1-ml samples were removed, the cells were sedimented at 4'C, and then resuspended in 1 ml of fresh buffer at 15'C. 40-,Ju samples were then transferred to a series of tubes that contained 4 ml of buffer in the presence and absence of unlabeled insulin (1.67 ,uM, 15°C). At intervals, duplicate tubes of each set were sedimented, the supernate was removed, and the radioactivity in the cell pellet was counted. The radioactivity on the cells expressed as a percent of the radioactivity present at T = 0 is plotted as a function of the time elapsed after dilution. Each point is the mean of duplicates; duplicates differed by <5%. In each case, nonspecific binding (i.e., that which bound in the presence of 10 ,ug/ml insulin in the original association) was subtracted to yield specific counts. proposed in the pathogenesis of three myasthenia gravis, Graves' disease, and drome of extreme insulin resistance with nigricans, type B (1, 5, 6 ).
Effect of Antireceptor
In the latter syndrome, we have previ4 acterized the circulating immunoglobulins to and block the membrane receptors (2, 3) . In this report, we analyze in depth of these antibodies on 1251-insulin bindin better understand the nature of their intern the insulin receptor.
With insulin receptors on a human lymr cell line (IM-9) as a model, inhibition i1 undiluted serum is rapid, with the tv titered sera causing nearly maximal inhil <5 min exposure to the cells (Fig. 1) . I] the extent of inhibition is quite markei least 95% of specific insulin binding beii after incubation with serum B-2. Maximal may not have been reached after 3 h, part sera B-i and B-3. Studies with appropriately diluted seru Con troli permitted comparative studies of time-course and temperature dependence of the inhibitory effect (Fig. 2) . They indicate similar rates of onset of inhibiSerum B2 tion, and a single disparity with regard to temperaSerum B1 ture dependence ofthe effect. That is, whereas sera B-2 and B-3 produced maximum inhibition of insulin binding when exposed to cells at 37°C, serum B-i was Serum B3 maximally effective at 22°C. This strongly suggests that serum B-i recognizes a binding determinant on the membrane different from those recognized by sera B-2 or B-3. It should also be noted that the temperature dependence of antibody effect for all three sera is clearly different from that for insulin binding to its receptor (7) . At steady state, insulin binding is characteristically greater at 40 than at 22°C and this in turn is greater than that at 370C. In contrast to the rate of onset of inhibition, the rate of return of binding when cells are washed and placed in fresh buffer is very slow (Fig. 3) . This presumably reflects slow dissociation of bound antibody, and may be the consequence of bivalent binding of antibody to clustered insulin receptors. This slow dissociation rate, which differs markedly With serum B-i, nearly all of the binding inhibition diseases-may be explained by reduction of R0, with little or I the syn-no effect on receptor affinity for insulin. In contrast, acanthosis after exposure to sera B-2 and B-3, both Ro and affinity are reduced, but major reductions of receptor ously char-affinity predominate. It should be noted that reducs that bind tions in R0 and affinity in this analysis may be confor insulin sidered analogous to the effects produced by "noni the effect competitive" and "competitive" inhibitors, respecg, so as to tively, in the terminology of enzymology. Although action with mechanistic explanations for the nature of these effects on Ro and affinity are speculative, we might )hoblastoid envisage a reduction of Ro to be the result of an nduced by essentially irreversible occupation of the receptor vo highest in such a way as to completely prevent insulin bition after binding. On It should be stressed, however, that the major mechanism by which these antibodies appear to reduce receptor affinity for insulin is by reducing the association rate constant for insulin binding. This is clearly distinguished from the mechanism by which insulin reduces the affinity of its receptor (i.e., negative cooperativity), which is through an acceleration of the dissociation rate.
The ability of insulin to induce site-site interactions of the negatively cooperative type is a characteristic feature of insulin receptors (12) . It is of interest that treatment of cells with antireceptor antibodies appears to reduce the capacity of insulin to induce this phenomenon. Evidence on this point derives from both steady-state and kinetic data. First, analysis of steady state data for '25I-insulin binding to control cells with the "average affinity profile" (vide supra) is consistent with a fall in average receptor affinity with increasing receptor occupancy. This finding reflects negatively cooperative site-site interactions between insulin receptors, as demonstrated by direct kinetic experiments (12) . When cells are treated with antireceptor antibodies, average affinity for insulin is reduced at low levels of receptor occupancy, with little or no reduction in affinity observed at the highest degrees of receptor occupancy. Thus, the degree to which receptor affinity is reduced with progressive occupancy by insulin is less marked in antibody-treated than in control cells. Further, treatment with each serum reduced the extent of negative cooperativity as determined by the direct kinetic experiment of De Meyts et al. (12) . The dissociation of 1251-insulin from cells pretreated with antireceptor antibody was accelerated to a lesser degree by unlabeled insulin than was the dissociation of 1251-insulin from untreated cells. This resistance to the induction of negative cooperativity by insulin was seen over a wide range of insulin concentrations.
Thus, both kinetic and steady-state data suggest that antireceptor antibody binding reduces the capacity for negative cooperativity induced by insulin, although the mechanism of this effect may be complex. Several speculations seem reasonable. First, because negative cooperativity induced by insulin is a function of insulin binding to its receptor, we would expect inhibition of insulin binding caused by antibody to inhibit the ability of a given amount of insulin to induce negative cooperativity. According to this model, any insulin that did bind would induce cooperativity to the usual extent. Our current inability to analyze the dissociation data in a precise quantitative manner makes it difficult to compare the extent of binding inhibition with the reduction of cooperativity, and thereby determine whether binding inhibition is the sole mechanism for reduced cooperativity. However, binding of antireceptor antibodies might additionally impair the capacity for negative cooperativity by inducing slight alterations in the conformation of the receptor or its subunits (17) . It is important to note that the addition of antibody to the diluting media in a concentration sufficient to reduce tracer insulin binding by 80% did not induce an acceleration in the dissociation rate of insulin bound to control cells, i.e., unlike insulin, the binding of antibody to the membrane did not cause cooperative interactions of the negative type between insulin receptors. 2 Thus, detailed analysis reveals that the inhibition of insulin binding caused by antireceptor antibodies may involve a variety of mechanisms. These include competitive occupancy of receptor sites, alteration of insulin association and dissociation kinetics, and interference with site-site interactions between receptors. Further use of these antibodies as probes of the insulin receptor may exploit one or more of these interesting effects. In addition, these antibodies may serve as a model for other studies of antibody effects on the interaction of ligands with important cell membrane receptors.
